ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc (EPRX)

3,39
-0,01
( -0,29% )
Mis à jour : 17:56:15

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
3,39
Prix Achat
3,16
Prix Vente
3,35
Volume échangé
8 647
3,15 Fourchette du Jour 3,39
2,20 Plage de 52 semaines 4,08
Cap du marché
Clôture Veille
3,40
Ouverture
3,31
Dernière Transaction
7
@
3.15
Dernière heure de transaction
17:12:37
Volume financier
US$ 28 541
VWAP
3,3007
Volume moyen (3 m)
15 475
Actions en circulation
35 622 553
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-5,87
Bénéfice par action (BPA)
-0,79
Chiffre d'affairess
-
Bénéfice net
-28,22M

À propos de Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient be... Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Victoria, British Columbia, Can
Fondé
-
Eupraxia Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker EPRX. Le dernier cours de clôture d'Eupraxia Pharmaceuticals était de US$3,40. Au cours de la dernière année, les actions de Eupraxia Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 2,20 à US$ 4,08.

Eupraxia Pharmaceuticals compte actuellement 35 622 553 actions en circulation. La capitalisation boursière d'Eupraxia Pharmaceuticals est de US$121,12 million. Eupraxia Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -5.87.

EPRX Dernières nouvelles

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months PR Newswire VICTORIA, BC, Nov. 20, 2024...

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting PR Newswire VICTORIA, BC, Nov. 14, 2024 VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia...

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November...

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, Nov. 12, 2024 One...

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire VICTORIA, BC, Nov. 7, 2024 VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.01-0.2941176470593.43.633.05135073.32344402CS
40.020.5934718100893.374.082.78234943.42137838CS
120.7528.40909090912.644.082.2154753.13873119CS
260.6825.09225092252.714.082.2118952.94920754CS
52-0.16-4.507042253523.554.082.2165692.9173551CS
156-0.16-4.507042253523.554.082.2165692.9173551CS
260-0.16-4.507042253523.554.082.2165692.9173551CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
CTNTCheetah Net Supply Chain Service Inc
US$ 5,3928
(188,39%)
102,5M
ZJKZJK Industrial Company Ltd
US$ 15,60
(146,06%)
16,63M
JANXJanux Therapeutics Inc
US$ 62,845
(56,41%)
4,63M
GWAVGreenwave Technology Solutions Inc
US$ 0,5515
(51,10%)
310,66M
CRDOCredo Technology Group Holding Ltd
US$ 71,63
(49,85%)
10,85M
REVBRevelation Biosciences Inc
US$ 0,5502
(-42,08%)
3,04M
OMEXOdyssey Marine Exploration Inc
US$ 0,4719
(-36,67%)
3,09M
GELSGelteq Ltd
US$ 2,60
(-31,95%)
221,4k
XTKGX3 Holdings Company Ltd
US$ 1,1401
(-27,84%)
368,99k
STSSSharps Technology Inc
US$ 2,42
(-27,84%)
182,68k
GWAVGreenwave Technology Solutions Inc
US$ 0,5515
(51,10%)
310,66M
SMCISuper Micro Computer Inc
US$ 41,1164
(-2,10%)
150,29M
CTNTCheetah Net Supply Chain Service Inc
US$ 5,3928
(188,39%)
102,5M
CHRSCoherus BioSciences Inc
US$ 1,98
(44,53%)
96,01M
CTORCitius Oncology Inc
US$ 1,48
(45,10%)
94,19M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock